1Hegde PS,Rusnak D,Bertiaux M,et al.Delineation of molecular mechanisms of sensitivity to Iapatinib in breast canner cell lines using global gene expression profiles[J].Mol Cancer Ther,2007,6 (5):1629-1640.
2Ito Y,Tokudome N,Sugihara T,et al.Does lapstinib,a small-moleeule tyrosine kinase inhibitor,constitute a breakthrough in the treat ment of breast cancer[J].Breast Cancer,2007,14(2):156-162.
3Medina PJ,C,oadin S.Lapatinib:a dual inhibitor of human epidermal growth factor receptor tyrosine kinases[J].Clin Ther,2008,30(8):1426-1447.
5Lin NU,Diéras V,Paul D,et al.Muhi-eenter phase Ⅱ study of lapatinib in patients with brain metastuses from HER2-positive breast caneer[J].Clin Cancer Res,2009,15(4):1452 -1459.
6Engnl RH,Kaklamani VG.HER2-positive breast cancer:current and future treatment stmtagies[J].Drugs,2007,67 (9):1329-1341.
7Porters CC,Walshe JM,Rosing DR,et al.Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with[corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer[J].Clin Cancer Res,2009,14(9):2710 -2716.
8Albanell J,Montagnt C,Jones ET,et al.A phase Ⅰ study of the safety and pharmacokinetics of the combination of pertuzumab (thuMab 2C4) and capeeitsbine in patients with advanced solid tumors[J].Clin Cancer Res,2008,14(9):2726 -2731.
3Johnston SR, Leary A. Lapatinib: a novel EGFR/Her2 tyrosine kinase inhibitor for cancer. Drugs Today ( Barc), 2006, 42:441- 453.
4Lackey KE. Lessons from the drug discovery of lapatinib, a dual ErbBl/2 tyrosine kinase inhibitor. Curr Top Med Chem, 2006, 6:435-460.
5Nelson MH, Dolder CR. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother, 2006, 40 : 261-269.
6Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumorderived cell lines in vitro and in vivo. Mol Cancer Ther, 2001, 1 : 85-94.
7Xia W, Liu LH, Ho P, et al. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene, 2004, 23:646-653.
8Xia W, Gerard CM, Liu L, et al. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene, 2005, 24: 6213-6221.
9Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against Her-2- overexpressing and trastuzumab-treated breast cancer cells. Cancer Res, 2006, 66:1630-1639.
10Lipton A, Leitzel K, Ali SM, et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer, 2005, 104:257-263.
7Fisher B,Digam J,et al.Five versus more tban five years of tamoxifen therapy for lymph node-negative breast cancerupdated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial[J].J Natl Cancer Inst,2001,93:684-690.
8Wright MH,Calcagno AM,Salcido CD,et al.Brcal breast tumors contain distinct CD44+/CD24(-)and CD133+ Cells with cancer stem cell characteristics[J].Breast Cancer Res,2008,10(1):R10.
10Slamon DJ,Leyland-Jones B,Shak S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J].N Engl J Med,2001,344(11):783-792.
